Victory Capital Management
APGE

Victory Capital Management’s Apogee Therapeutics APGE Stock Holding History

Victory Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Sell
87,953
-7,184
-8% -$647K 0.01% 1067
2026
Q1 		$8.01M Sell
95,137
-13,130
-12% -$954K 0.01% 1158
2025
Q4 		$8.17M Sell
108,267
-108,946
-50% -$6.86M ﹤0.01% 1116
2025
Q3 		$8.63M Sell
217,213
-37,557
-15% -$1.43M 0.01% 1158
2025
Q2 		$11.1M Buy
254,770
+21,787
+9% +$829K 0.01% 1077
2025
Q1 		$8.7M Buy
232,983
+9,921
+4% +$384K 0.01% 1107
2024
Q4 		$10.1M Sell
223,062
-123,296
-36% -$6.29M 0.01% 1086
2024
Q3 		$20.3M Buy
346,358
+190,092
+122% +$9.11M 0.02% 842
2024
Q2 		$6.15M Buy
156,266
+56,607
+57% +$2.75M 0.01% 1205
2024
Q1 		$6.62M Buy
99,659
+83,839
+530% +$3.66M 0.01% 1169
2023
Q4 		$442K Hold
15,820
– – ﹤0.01% 2028
2023
Q3 		$337K Buy
+15,820
New +$349K ﹤0.01% 2088

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Victory Capital Management's APGE Position: Q2 2026 in Review

Victory Capital Management reduced its Apogee Therapeutics (APGE) stake by 7.6% in Q2 2026, selling an estimated $647K and leaving 87,953 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #1067.

Victory Capital Management first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. The position peaked at $20.3M in Q3 2024. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Victory Capital Management held 87,953 shares of Apogee Therapeutics worth $11.7M as of Q2 2026.
  • Victory Capital Management sold 7,184 Apogee Therapeutics shares in Q2 2026, an estimated $647K.
  • Apogee Therapeutics made up 0.01% of Victory Capital Management's portfolio in Q2 2026, its #1067 holding.
  • Victory Capital Management first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Victory Capital Management's Apogee Therapeutics position peaked at $20.3M in Q3 2024.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.